New Zealand markets open in 7 hours 48 minutes

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.64000.0000 (0.00%)
As of 10:09AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.6400
Open1.6100
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.6100 - 1.6800
52-week range0.9700 - 5.0900
Volume8,904
Avg. volume30,941
Market cap7.142M
Beta (5Y monthly)0.56
PE ratio (TTM)N/A
EPS (TTM)-4.2400
Earnings date23 Apr 2024 - 25 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.20
  • GlobeNewswire

    Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

    Plus now has $23 million in active awards support for the Company’s targeted radiotherapeutic pipeline Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract finalization AUSTIN, Texas, April 22, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has been

  • GlobeNewswire

    Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

    The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’ scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (CNS) cancers Dr. Blouw is an expert in CNS tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (

  • GlobeNewswire

    Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference

    AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida. NCCN 2024 Annual Conference – Orlando World Center Marriott